Physician profile
Ryan D Nicklas
NPI 1770075533
$549.59
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.11 · 2020: $125 · 2021: $389 · 2022: $22.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $164.41 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $124.99 | 2020 | |
| Abiomed | $109.58 | 2021 | |
| Trevena, INC. | $58.08 | 2021 | |
| Abbott Laboratories | $22.36 | 2021 | |
| Draeger Medical Systems, INC | $22.00 | 2022 | |
| Acacia Pharma INC | $18.33 | 2021 | |
| Hemosonics LLC | $16.73 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Nicklas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.